HARPOON Therapeutics

Spearheading Immunotherapies

SVB SECURITIES GLOBAL BIOPHARMA CONFERENCE FEBRUARY 14, 2023

Nasdaq: HARP

Forward-looking Statements



This presentation and accompanying oral commentary contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "target," "estimate" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Harpoon's expectations and assumptions as of the date of this presentation. Each of these forward-looking statements involves risks and uncertainties that could cause Harpoon's clinical development programs, future results or performance to differ significantly from those expressed or implied by the forward-looking statements. Forward-looking statements contained in this presentation and accompanying oral commentary include, but are not limited to, statements about the progress, timing, scope, design and anticipated results of clinical trials, the timing of the presentation of data, the association of data with potential treatment outcomes, the development and advancement of platforms and product candidates, and the timing of development milestones for platforms and product candidates, expectations of our cash runway and future business, strategy and financial performance. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during clinical studies, clinical trial site activation or enrollment rates that are lower than expected, unanticipated or greater than anticipated impacts or delays due to the COVID-19 pandemic, changes in expected or existing competition, changes in the regulatory environment, the uncertainties and timing of the regulatory approval process, the risk that initial or interim results from a clinical trial may not be predictive of the final results of the trial or the results of future trials, the risk that trials may be delayed and may not have satisfactory outcomes, and unexpected litigation or other disputes that impede clinical trial progress. Other factors that may cause Harpoon's actual results to differ from those expressed or implied in the forward-looking statements in this presentation and accompanying oral commentary are discussed in Harpoon's filings with the U.S. Securities and Exchange Commission, (SEC) including under "Risk Factors" in Harpoon Therapeutics' guarterly report on Form 10-Q for the guarter ended September 30, 2022, filed with the SEC on November 14, 2022 and our other filings from time to time. Except as required by law, Harpoon assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Certain information contained in this presentation and statements made orally during this presentation relate to or are based on studies, publications, surveys and other data obtained from third-party sources and Harpoon's own internal estimates and research. While Harpoon believes these third-party studies, publications, surveys and other data to be reliable as of the date of this presentation, it has not independently verified, and makes no representations as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, no independent source has evaluated the reasonableness or accuracy of Harpoon's internal estimates or research and no reliance should be made on any information or statements made in this presentation relating to or based on such internal estimates and research.



Clinical-Stage Immuno-Oncology Company Directing T Cells to Kill Tumors



Advancing a Portfolio of Novel T Cell Engagers (TCEs)

Clinical Pipeline

Addressing broad patient populations

- Clinical-stage T cell engagers across multiple indications
- Clinical benefit seen in hematological and solid tumor settings:
 - Confirmed responses, tumor lesion reductions deepening over time in our ongoing Phase 1 clinical studies
- Emerging clinical data validate
 TriTAC platform designed to
 maximize the therapeutic window

Novel TCE Platforms

Solid and hematological tumors

- Platform technologies allowing for "off-the-shelf" T cell therapies
- Treating broad patient populations with unmet needs
- Addressing solid and hematologic malignancies
- Each platform designed to maximize the therapeutic window

Strong Capabilities

Industry veterans developing novel TCEs

- Deep expertise in oncology, T cell engagement, and protein engineering
- Cash runway expected to fund operations through end of 2023
 - \$66.1M in cash, cash equivalents & short-term marketable securities*
- Strong patent protection across platforms and programs



Broad Pipeline of Immuno-Oncology Programs Clinical-Stage TriTAC[®] Programs, Novel TCE Platforms



Program	Indication(s)	Stage of Development			Partner	
		Preclinical	Phase 1	Phase 2	Phase 3	
HPN217 ¹ (BCMA)	Multiple Myeloma					abbvie ¹
HPN328 ² (DLL3)	Small Cell Lung Cancer / Other Solid Tumors					atezolizumab Supply Agreement
HPN601 (EpCAM)	Multiple Solid Tumors					
Preclinical Candio	dates					
TriTAC/ProTriTAC	Oncology					obbvie ³
TriTAC-XR	Oncology / Non-Oncology					


TriTAC ProTriTAC TriTAC-XR

- (1) AbbVie retains an option to worldwide exclusive rights (HPN217)
- (2) Roche supply agreement established for the use of atezolizumab in combination with HPN328
- (3) AbbVie entered in a discovery platform collaboration to select a fixed number of targets from these platforms




TriTAC® HPN217 Targeting BCMA

Interim Data Presented at ASH 2022





- 58% overall 5-year survival rate in U.S. increasing over time¹, creating need for multiple lines of therapy
- BCMA agents beginning to redefine RRMM treatment, with opportunities to improve upon tolerability, efficacy, and accessibility
- BCMA agents with improved tolerability have future potential to be developed in the early line setting








¹ Over time period 2012 and 2018 Cancer stats Facts: Myeloma <u>https://seer.cancer.gov/statfacts/html/mulmy.html</u> BCMA means B-cell Maturation Antigen; RRMM means Relapsed/Refractory Multiple Myeloma, SCT means Stem Cell Transplant (Accessed Oct 2022); Global Data, 2019; Strassel L; Schreder, M, 2021; KOL Interviews

HPN217-3001 Phase 1/2 Trial Design Relapsed/Refractory Multiple Myeloma





Fixed- and Step-Dose Escalation Cohorts: 3-6 patients per dose level; Backfilling permitted; * Step-Dose Regimen

Key Eligibility Criteria

- Relapsed/refractory multiple myeloma
- ≥3 prior therapies, including PI, IMID, and anti-CD38
- Prior BCMA-targeted therapies allowed

Trial Design

- Primary Objectives: Safety, PK, Establish MTD or RP2D
- Secondary Objectives: Clinical Activity per IMWG Criteria

Dosing & Administration

- HPN217 administered by 1-hour IV infusion as flat dose
- Premedication for Cytokine Release Syndrome (CRS) prophylaxis

Next Steps

- Currently enrolling initial bi-weekly dosing cohort
- Dose optimization and backfill ongoing, with final cohort plans to be based upon emerging data



HPN217: Study Patient Population Represents Real-World, Late-Line Population with High-Risk Features



Baseline Characteristics and Demographics

Baseline Characteristics	Total N = 62
Age (yr), Median (range) Age <u>></u> 75 years, n (%)	70 (38 – 83) 12 (19%)
Time Since Initial MM Diagnosis (yr), Median (range)	8 (1 – 20)
Baseline sBCMA (ng/mL), Median (range)	240 (27– 2444)
ECOG, n (%) 0 1 Missing	14 (23%) 46 (74%) 1 (2%)
Revised ISS Stage at Study Entry, n (%) I II III Missing	16 (26%) 17 (27%) 26 (42%) 3 (5%)

Prior Systemic Therapies

Prior Cancer Therapy	Total N = 62
Prior Systemic Therapies, Median (range)	6 (2-19)
Prior Transplantation, n (%)	46 (74%)
Exposure Status, n (%) Triple-class ^a exposed Penta-drug ^b exposed BCMA exposed	58 (94%) 41 (66%) 13 (21%)
Relapsed/Refractory Status, n (%) Triple-class ^a refractory ^c Penta-class ^b refractory ^c BCMA refractory ^c	47 (76%) 26 (42%) 11 (18%)

^aIMiD, PI, and anti-CD38; ^bAt least 2 Pis, at least 2 IMiDs, and at least 1 anti-CD38 antibody; ^cNo response to regimen or discontinued regimen due to progression, adapted from Rajkumar et al (Blood 2011)





Common Treatment-Emergent Adverse Events (Regardless of Relationship), >15%

AE Preferred Term	All Grades (N=62) ^a	<u>></u> Grade 3 (N=62) ^a
Anemia	27 (44%)	21 (34%)
Fatigue	20 (32%)	2 (3%)
Cytokine release syndrome ^b	17 (27%)	0 (0%)
Headache	15 (24%)	0 (0%)
Hypokalemia	13 (21%)	2 (3%)
Nausea	13 (21%)	0 (0%)
Back Pain	11 (18%)	1 (2%)
Diarrhea	11 (18%)	1 (2%)
Hypophosphatemia	11 (18%)	4 (7%)
AST increased	11 (18%)	5 (8%)
Cough	11 (18%)	0 (%)
Arthralgia	10 (16%)	1 (2%)
Neutrophil count decreased	10 (16%)	8 (13%)
Dyspnea	10 (16%)	2 (3%)
ALT increased	9 (15%)	4 (7%)
Constipation	9 (15%)	0 (%)
Hypercalcemia	9 (15%)	1 (2%)

Dose Limiting Toxicity

- Fixed Dose: 2 patients at 2.86 mg/week, reversible transaminitis (Gr 3, n=1; Gr 4, n=1), no clinical sequelae
- Step Dose: No DLTs; MTD not reached

• Neurologic/Psych Events^c

- Treatment related events reported in 10 patients
 - All events Grade 1 2
 - Most common: Headache (n=6) and Confusion (n=2)

• Infections^d


- Reported in 28 (45%) patients (Gr 3/4, 16%)
- Most common: Pneumonia (n=6), upper respiratory tract infection (n=5) and urinary tract infection (n=5)


^a Grading per CTCAE v5.0; ^b Grading per ASTCT 2019 Criteria; ^c SOC nervous system disorders and psychiatric disorders; ^d SOC infections and infestations



HPN217: ORR and CRS Rates Suggest Potentially Differentiated Profile with Widened Therapeutic Index










*Note: Unaudited patient data based on entries provided in open clinical database as of 10/17/2022. Responses per Investigator Assessment (subject to change) ¹Highest 2 dose levels with disease-evaluable patients at each timepoint Q1W; ²Highest 2 dose levels with patients who received <u>></u>1 dose Q1W or Q2W

HPN217: Time on Treatment at Target Doses > 2.15mg **Deep Early Responses Observed at Highest Exposures**



* All patients Q1W schedule with exception of patients denoted

MONTHS

Note: Based on available data in unaudited patient database as of 10/17/2022; confirmed and unconfirmed responses per Investigator Assessment (subject to change)



HPN217: Summary



Profile Emerging with Opportunity to be Best-in-Class T Cell Engager Targeting BCMA

Active Agent¹

- 77% (10/13) ORR observed across highest step-dose levels (12 and 24 mg)
- Responses occurred early and were durable; for patients with at least 9 months follow up, the median responder time on treatment is 12 months
- 18 of 21 responders remain on study treatment with sustained response, with many responses deepening over time

Well Tolerated Safety Profile Emerging

- Transient CRS in 29% of patients across highest step-dose levels (12 and 24mg)
- Post ASH, 1 patient experienced Gr3 CRS and Gr1 ICANS at 24 mg target dose followed by posttraumatic Grade 5 subdural hematoma
- Overall, low incidence of CRS across the patient population studied to date

Anticipated Near-Term Milestones


- Dose expansion and backfill cohorts continue to enroll at target dose of 12mg and 24mg
- Study enrollment anticipated to complete in 1H 2023, with up to potentially 94 patients, based on data from dose escalation cohorts




¹ Relative to other BCMA-targeted TCEs in heavily pretreated patients across the highest step-dose cohorts ² ICANS means Immune effector cell-associated neurotoxicity syndrome

Note: Unaudited patient data based on entries provided in open clinical database as of 10/17/2022 (subject to change)

TriTAC® HPN328 Targeting DLL3





¹Atezolizumab and Durvalumab approved for 1L ES-SCLC in combination with platinum-doublet chemo and continued in maintenance for patients with ≥SD;



² Lurbinectedin has accelerated approval in the U.S. only.

Source: NCCN Guidance; Physician Interviews 2021



• Target population

- SCLC relapsed after platinum chemotherapy
- Other high-grade neuroendocrine cancers R/R to standard of care (SOC) or no SOC available

• Trial objectives

- Assess safety and tolerability at increasing dose levels
- Characterize PK and PD
- Evaluate preliminary anti-tumor activity

• Dosing and administration

- Weekly IV infusion

• Status

- 29 patients enrolled at the end of 2022
- Currently enrolling backfill patients in 1mg 6mg cohort; enrollment continuing in dose escalation 1mg – 12 mg cohort

Baseline Characteristics	Total N = 22
Age (yr), Median (range)	61 (43 – 73)
ECOG performance status 0-1, n (%)	22 (100)
Brain / Liver metastases, n (%)	8 (36) / 11 (50)
Disease	n (%)
Small Cell Lung Cancer	15 (68)
Neuroendocrine Prostate Cancer	2 (9)
Other Neuroendocrine Neoplasm	5 (23)
Prior Lines of Therapy	n (%)
1	5 (23)
2	5 (23)
≥3	12 (54)
Median (range)	3 (1-6)
Prior immune checkpoint inhibitor (α PD-1/ α CTLA4, α PD-L1)	18 (82)



HPN328: Safety Summary



- Recent priming dose DLTs inform optimization of priming dose to support further escalation of target dose¹
- TriTAC platform designed to minimize CRS risk and allow for greater escalation of target dose, and re-escalation of target dose is underway
- No DLTs at target dose
- Target dose MTD not yet reached





• HPN328 was observed to be active ¹

- 71% (5/7) of SCLC patients at doses ≥1.215mg had target lesion shrinkage
- 25% (3/12) of SCLC patients across all doses with >30% Target Lesion Shrinkage
- 1 Confirmed Partial Response, durable beyond 6 Months
- Treatment duration \geq 5 months was observed in 7 of 20 (35%) patients
- Median half-life of 71 hours, with linear pharmacokinetics
- Update as of January 2023: 1 additional Confirmed Partial Response was observed in a SCLC patient in the 2-12mg QW cohort who remains on treatment



HPN328 Patient Case 1: Relapsed ES-SCLC 53% Reduction in Sum of Target Lesion Diameters at Week 10: Confirmed PR Data as of October 10, 2022




Week 10 On Treatment

Patient History

- 61-year-old female
- Diagnosed Jan 2021 with extensivestage SCLC
- Location of metastases:
 - TLs: lung, liver x2, lymph nodes x2
 - Non-TLs: lung x2, liver
- Prior systemic treatment:
 - carboplatin + etoposide + atezolizumab
- Time on most recent prior systemic treatment: 20.1 weeks
- Upon study entry, <u>stable disease as</u> <u>best response</u> to most recent prior systemic treatment

Results


- Initiated HPN328 at 1.215mg/week, later dose escalated
- <u>Confirmed PR at week 10</u>
- Continued treatment with HPN328 for 33 weeks







gung

Pre-Treatment







53% reduction at wk 10

Unaudited patient data based on entries provided in open clinical database as of 10/10/2022 (subject to change)



HPN328 Patient Case 2: Relapsed ES-SCLC

72% Reduction in Sum of Target Lesion Diameters

Deepening of response over time continuing beyond ASCO 2022 data

Patient History

- 67-year-old male •
- Diagnosed in April 2020 with extensive-• stage SCLC
- Location of metastases •
 - TLs: liver x2, lymph nodes x2
 - Non-TLs: liver, lymph nodes x2, spleen, bone, brain
- Prior systemic treatment •
 - Carboplatin + Etoposide + Toripalimab
 - Cisplatin + Etoposide
 - Lurbinectedin
- Time on most recent prior systemic ٠ treatment
 - 10.9 weeks
- Upon study entry, partial response as best • response to most recent prior systemic treatment but unable to tolerate further treatment

Results

- HPN328 3.6 \rightarrow 7.2 mg/week (increased to 12 mg/week)
 - Well tolerated
- 72% reduction in sum of target lesion diameters
 - Asymptomatic brain metastasis identified at week 2 ٠
 - Systemic disease responding to HPN328
 - RECIST v1.1: Target Lesions: PR; Overall: PD
 - 60% cells positive for DLL3
- Deepening of radiographic target lesion response over time
- Remains on HPN328 treatment beyond 54 weeks
 - At ASCO 2022 (April 21, 2022 data) was at 27 weeks
 - Current data: ongoing clinical benefit observed beyond 1 year


Baseline






Deep, durable target lesion shrinkage


Data as of October 10, 2022













HPN328: Anticipated Next Steps

- Continue enrollment in the Phase 1 dose exploration study
 - Monotherapy cohorts:
 - 1 mg 6 mg step dose cohort enrolled and cleared for escalation
 - 1mg 12mg step dose cohort enrolling
 - 29 patients were enrolled at year end 2022
 - Enrollment started in Q2W dosing cohorts for HPN328 monotherapy planned in 1H 2023
 - Combination cohorts:
 - Begin enrollment of additional cohorts in the Phase 1 dose escalation study evaluating HPN328 in combination with atezolizumab in SCLC
- Provide Phase 1 interim data in mid-2023 for the highest target doses studied
 - Plan for enrollment up to potentially 70 patients with ≥1 on-treatment scan by end of Q2 '23^{*}
- Plan for enrollment of up to 100 patients in monotherapy and combination therapy dose cohorts (including backfill) by mid-2023^{*}
- Complete Phase 1 enrollment of potentially up to 130 patients in monotherapy and combination cohorts in 2H 2023 *



Summary and Anticipated Milestones

- Advancing pipeline of next-generation T cell engagers address broad patient populations with high unmet needs
- Strategic prioritization to focus resources on ongoing clinical programs in or nearing the clinic
- Clinically meaningful activity in hematology and solid tumor Phase 1 studies
- Current cash and equivalents of \$66.1 million* expected to fund operations to the end of 2023

HPN217 (BCMA):

- Ongoing patient enrollment in the Phase 1 trial;
- Complete enrollment in 1H-2023

1H

2023

HPN328 (DLL3):

• Begin enrolling additional cohorts in the Phase 1 dose escalation study evaluating HPN328 in combination with atezolizumab in SCLC in 1H-2023

HPN601 (EpCAM):

 Harpoon expects to be ready to file an IND in 1H-2023 to enable a Phase 1 dose exploration study, pending available resources



HPN217 (BCMA):

- Patient follow up and completion of final data package to deliver to AbbVie by YE
- Prepare for EOP1 and Phase 2 planning meeting with FDA

HPN328 (DLL3):

- Complete enrollment in monotherapy and combination arms
- Provide interim data for the highest target doses studied in mid-2023
- Identify RP2D; prepare for EOP1 and Phase 2 planning meeting with FDA

HARPOON

HARPOON Therapeutics

Thank You!

Nasdaq: HARP